(Q36835533)

16 August 2017

1 reference

title

Emerging targets of biologic therapies for rheumatoid arthritis (English)

1 reference

16 August 2017

0 references

2

Ulf Müller-Ladner

1 reference

16 August 2017

Ingo H Tarner

1

1 reference

PubMed ID

17538565

16 August 2017

Steffen Gay

series ordinal

3

1 reference

16 August 2017

1 June 2007

1 reference

Nature Clinical Practice Rheumatology

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

6

1 reference

16 August 2017

336-345

1 reference

Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis.

16 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: effect of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

Rheumatoid arthritis: non-tumor necrosis factor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Understanding the IL-23-IL-17 immune pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Mechanisms of Disease: the link between RANKL and arthritic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

The effect of a single dose of osteoprotegerin in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

B cell depletion therapy in rheumatic disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

BLyS and APRIL in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Small molecular anti-cytokine agents.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Role of adipose tissue as an inflammatory organ in human diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Different effects of adiponectin isoforms in human monocytic cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Towards a pro-inflammatory and immunomodulatory emerging role of leptin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Adipocytokines in synovial fluid

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

The potential of adiponectin in driving arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Resistin, an adipokine with potent proinflammatory properties

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Signal transduction in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Inhibiting inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Gene analysis for exploring the effects of drugs in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0506

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0506

1 reference

release_igsg2vkl45g3bmvkku7czyjdnq

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/igsg2vkl45g3bmvkku7czyjdnq

24 November 2022

mapped directly with Wikidata item

PubMed ID

17538565

1 reference

PubMed ID

17538565